Nucresiran

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameNucresiran
Drug Alias NameALNTTRsc-04
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceTransthyretin inhibitors
TargetsTransthyretin
Therapy Area/IndicationsTransthyretin amyloidosisCardiomyopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[38] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNa Pharma LtdAlnylam Pharmaceuticals IncPpd Pharmaceutical Development (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsTransthyretin amyloidosisCardiomyopathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A